FDA 483 - Cambrex Charles City, Inc.

Cambrex Charles City, Inc, an Active Pharmaceutical Ingredient Manufacturer, was cited for two observations during an FDA inspection. The firm failed to adequately investigate unexplained discrepancies, specifically an interfering chromatographic peak, and did not consistently follow written procedures for retain sample collection. These issues indicate deficiencies in quality control and adherence to established manufacturing practices.